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Abstract 
Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the 
integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. 
The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative 
between the Reference site MACVIA‑LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic 
Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active 
and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organiza‑
tion Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and 
Healthy Ageing has proposed a 5‑step framework for developing an individual scaling up strategy: (1) what to scale 
up: (1‑a) databases of good practices, (1‑b) assessment of viability of the scaling up of good practices, (1‑c) classifica‑
tion of good practices for local replication and (2) how to scale up: (2‑a) facilitating partnerships for scaling up, (2‑b) 
implementation of key success factors and lessons learnt, including emerging technologies for individualised and pre‑
dictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European 
Innovation Partnership on Active and Healthy Ageing.
Keywords: EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Chronic respiratory diseases, 
AIRWAYS ICPs, MACVIA, ARIA, Scaling up
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Background
Health and care services in Europe are undergoing 
changes to adapt systems to the growing demands caused 
by the expansion of chronic diseases and ageing. This 
restructuring involves the development and testing of 
innovative solutions as well as the implementation of 
the most successful pilots. The multitude of good prac-
tices developed throughout the European Union favours 
a comprehensive and multi-dimensional scaling-up strat-
egy at European level [1].
The European Commission DG Santé (Directorate 
General for Health and Food Safety) and DG CNECT 
(Directorate General for Communications Networks, 
Content and Technology) launched the European Inno-
vation Partnership on Active and Healthy Ageing (EIP on 
AHA) to enhance European Union competitiveness and 
to tackle societal challenges through research and inno-
vation (Table 1) [2].
Chronic respiratory diseases are the pilot for chronic 
diseases of the EIP on AHA Action Plan B3 [3, 4]. Several 
Page 3 of 18Bousquet et al. Clin Transl Allergy  (2016) 6:29 
effective plans exist in Europe for chronic respiratory 
diseases, but they are rarely deployed to other regions or 
countries. There is an urgent need for scaling up strate-
gies in order to (1) avoid fragmentation, (2) improve 
health care delivery across Europe, (3) speed up the 
implementation of good practices using existing cost-
effective success stories and (4) meet the triple win of the 
EIP on AHA:
  • Enabling European citizens to lead healthy, active and 
independent lives while ageing.
  • Improving the sustainability and efficiency of social 
and health care systems.
  • Boosting and improving the competitiveness of 
the markets for innovative products and services, 
responding to the ageing challenge and creating new 
opportunities for businesses.
This paper presents the scaling up strategy for 
chronic respiratory diseases strictly following the 
five-step framework scaling up strategy of the EIP on 
AHA. It may be used as a model for scaling up activi-
ties in other areas of the EIP on AHA and other chronic 
diseases.
AIRWAYS ICPs, the pilot for chronic diseases of the 
EIP on AHA
Chronic respiratory diseases include a variety of dis-
eases such as airway diseases (allergic and non-allergic 
asthma, rhinitis, rhinosinusitis and COPD), occupational 
lung diseases, sleep apnoea syndrome, interstitial dis-
eases, pulmonary vascular diseases and genetic diseases 
such as cystic fibrosis [5, 6]. Over 1 billion people in the 
world suffer from chronic respiratory diseases. They 
represent one of the priorities of the European Union 
(3053rd and 3131st Conclusions of the European Union 
Council, 2010 and 2011) [7, 8], World Health Organi-
zation (WHO 2013–2020 Noncommunicable Disease 
Action Plan) and the United Nations (High Level meet-
ing on Non-Communicable Diseases, 2011) [9]. The 2011 
Polish Presidency of the European Union Council made 
the prevention, early diagnosis and treatment of asthma 
and allergic diseases a priority for the European Union’s 
public health policy in order to reduce health inequali-
ties [7]. The early determinants of chronic respiratory 
diseases were reinforced during the Cyprus Presidency of 
the European Union Council [10]. The 2014 Italian Presi-
dency of the European Union Council has prioritized 
chronic respiratory diseases. Chronic respiratory dis-
eases represent a model of chronic diseases due to their 
prevalence, burden (e.g. 3 million annual deaths due to 
COPD), and comorbidities with other chronic diseases 
[11].
The initiative AIRWAYS ICPs (Integrated care path-
ways for airway diseases) [3] has been approved by the 
EIP on AHA as the model of chronic diseases of the 
B3 Action Plan. It is a GARD (Global Alliance against 
Chronic Respiratory Diseases, World Health Organi-
zation) Research Demonstration Project [5]. It was 
launched by NHS England (National Health Service, 
Newcastle, February 2014) [12] and has been endorsed 
by the EIP on AHA Reference Site Network.
The objectives of AIRWAYS ICPs are to launch a col-
laboration to develop practical multisectoral care path-
ways (ICPs) to reduce chronic respiratory disease burden, 
mortality and multimorbidity. AIRWAYS-ICPs proposes a 
feasible, achievable and manageable project from science 
to guidelines and policies using existing networks and 
stakeholders committed to the Action Plan B3 of the EIP 
on AHA and GARD [5]. It is implemented and scaled up 
in Europe by the EIP on AHA and globally with GARD.
AIRWAYS-ICPs has strategic relevance to the Euro-
pean Union Health Strategy and the World Health 
Organization Noncommunicable Diseases Action Plan 
(2013–2020). It adds value to existing public health 
knowledge (Table 2).
Table 1 Priority areas and action plans of the EIP on AHA
Priority areas Action plans
Prevention of diseases and health 
promotion
 A1 Innovative ways to ensure that 
patients adhere to their treatment
 A2 Innovative solutions for personal‑
ised health management, with 
focus on falls prevention
 A3 Action for preventing functional 
decline and frailty, with a particu‑
lar focus on malnutrition
Care and cure
 B3 Scaling up and replication of suc‑
cessful innovative integrated care 
models for CD amongst older 
patients, such as through remote 
monitoring
Active and independent living of 
older adults
 C2 Improving the uptake of interoper‑
able independent living solutions 
including guidelines for business 
models
Horizontal topics
 D4 Networking and knowledge sharing 
on innovation for age‑friendly 
environments
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Five‑step framework scaling up strategy of the EIP 
on AHA
Scaling up is often considered as a continuous process of 
change and adaptation that can take different forms [38]. 
The EIP on AHA has proposed a 5-step framework for 
developing an individual scaling up strategy. Area 5 has 
already used all these steps (Table 3). The scaling up pro-
cess of AIRWAYS ICPs has already been initiated, during 
an Action Plan B3 meeting in Brussels (March 2014).
In order to achieve a successful outcome for scaling up 
of innovative practice, the workforce should be appro-
priately educated in disease management, the neces-
sary skills (e.g. spirometry, inhaler technique) should be 
present, and sufficient capacity made available both for 
training and the extra time necessary in consultation 
with the individual patient. These were critical factors in 
achieving success in the Finnish asthma and COPD ten 
year plans [39]. Clinical recording systems need to be 
integrated to facilitate audit and appropriate sharing of 
clinical records.
Application of the EIP on AHA scaling up strategy 
to chronic respiratory diseases
Good practices in chronic respiratory diseases
AIRWAYS ICPs
Six commitments for action were submitted to the 
EIP on AHA to support AIRWAYS ICPs. Their good 
practices are complementary for the scaling up strategy 
(Table 4).
  • AIRWAYS ICPs study groups exist in all but 2 Euro-
pean Union countries (Luxembourg, Malta). They 
follow the GARD model deployed in Turkey [46, 47] 
and Italy [13, 48].
  • Governments of countries (e.g. Lithuania, Poland, 
Portugal, Turkey) or regions (e.g. Emilia-Romagna) 
are involved in AIRWAYS ICPs. One of the commit-
ments for action (Norway) is a joint action between 
the Ministry of Health of Finland and Norway [43].
Other international, national or regional projects
Many guidelines, ICPs and national plans exist for the 
most common chronic respiratory diseases (asthma, 
COPD, rhinitis).
  • The Finnish plans for asthma [40], allergy [41] and 
COPD [39], considered to be the prototypes of national 
plans for chronic respiratory diseases [42]. Polastma 
(Poland) is, in particular, derived from the asthma plan 
[35]. A review on the European asthma plans based on 
the Finnish Asthma Plan is available [42].
  • The Portuguese National Programme for Respira-
tory Diseases (PNDR), the first national programme 
including all respiratory diseases [45].
  • In the Netherlands, the SMART-formulated collabo-
rative National Action programme against Chronic 
Lung Diseases (NACL) aims to improve the cost-
effectiveness of respiratory prescribing, while reduc-
ing hospitalisation days, productivity loss, adolescent 
smoking, and mortality due to asthma and COPD. 
Both the Ministry of Health and the collective Health 
Insurers Netherlands are funding the programme 
[13].
  • Several national or regional plans on asthma, COPD, 
other chronic respiratory diseases and allergy.
  • Guidelines or strategies for asthma [49–52], COPD 
[53], rhinitis [21], rhinosinusitis [54] or severe asthma 
[55] (Table 5).
  • Care pathways provided by national institutions (e.g. 
NICE in the UK, National Institute for Health and 
Care Excellence or the Haute Autorité de Santé in 
France, ICP for acute asthma in children in Northern 
Ireland).
  • The World Health Organization guidelines for 
asthma and COPD in low-income settings (WHO 
PEN) [14].
  • Management plans already successfully tested in low 
and middle-income countries [15].
  • A common approach to severe asthma and allergic 
diseases [17, 19].
Table 3 The 5‑step framework of  EIP on  AHA scaling 
up strategy
Step Scaling up strategy Individual scaling up strategy
What to scale up
1 Database of good practices
2 Assessment of viability of the 
scaling up of good practices
3 Classification of good practices 
for local replication
How to scale up
4 Facilitating partnerships for 
scaling up
5 Implementation
Key success factors
and lessons learnt
Planning and initiating the 
service
Setting up a system for change
Organisational process and 
design choices
Training and skills for the work 
force
Appropriate resourcing for 
equipment
Integration of clinical record 
systems
Creating capacity
Monitoring, evaluation and  
dissemination
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  • In Spain, Polibienestar Research Institute is devel-
oping a Multi-Agent Simulator for people requir-
ing prolonged mechanical ventilation based on the 
validated LTCMAS [64] and following the Canadian 
model [65], which is easily replicable and transfer-
rable to other healthcare systems and to other dis-
eases. Moreover, this tool offers great possibilities 
for scaling-up and for supporting the decision-mak-
ing process of health professionals and policy-mak-
ers.
  • Multimorbidity guidelines for chronic respiratory 
diseases do not exist, except for rhinitis and asthma 
[21].
  • The risk for developing a COPD has only been stud-
ied in Italy and represents a chart risk applicable to 
the entire Europe.
  • Palliative approaches to care in chronic respiratory 
disease, and planning end-of-life decisions and care/
advanced care.
  • Guidelines with a specific target on old age adults do 
not exist. A Delphi process is ongoing.
Guidance documents for primary care
Some guidance documents are specifically directed to 
primary care—where most patients with chronic res-
piratory diseases are managed—such as COPD-Aus-
tralia (Lung Foundation Australia with Thoracic Society 
of Australia and New Zealand) and Asthma Manage-
ment in Australia (National Asthma Council Australia). 
IPCRG (International Primary Care Respiratory Group) 
has undertaken a mapping on national guidelines used 
by primary care for COPD, asthma, rhinitis, obstructive 
sleep apnea and stop smoking (https://www.theipcrg.org/
display/ResMapping).
Database
A centralized repository of evidence is developed to pre-
serve data throughout the lifecycle of the project. The 
repository is under development by the Commission.
Assessment of viability of the scaling up of good practices
The members of AIRWAYS ICPs, ARIA and GARD [6, 
13, 48] have experience in working together and have 
already scaled up several chronic respiratory disease 
good practices. Scaling up for ARIA and GARD follows 
the 7 key characteristics of the CORRECT features: Cred-
ible, Observable, Relevant, Relative advantage, Easy and 
Compatible [66, 67]. The success of the scaling up strat-
egy and its long-term viability (over 15  years for ARIA 
and 8 years in GARD) has been demonstrated. GARD has 
been scaled up in several countries at governmental lev-
els [13, 46–48].
Members of 13 EIP on AHA Reference Sites have 
agreed on the AIRWAYS ICPs concept and are co-
authors of the paper [3]. A meeting of all EIP on AHA 
Reference Sites was co-organised by the Région LR, 
North England and the EIP on AHA Reference Site Col-
laborative Network to scale up AIRWAYS ICPs in all Ref-
erence Sites (October 21, 2014).
The viability of ARIA and GARD has been demon-
strated. The viability of AIRWAYS ICPs will be analysed 
according to the set of parameters provided by the Com-
mission in the near future. The analysis will be carried 
out within 6 months by an AIRWAYS ICPs expert panel 
and revised by an independent expert panel (6 additional 
months). The meeting for the analysis of the viability 
took place in Lisbon (Directorate General of Health of 
Portugal), July 1-2, 2015 in collaboration with the World 
Health Organization GARD [68].
Table 5 An example of scaling up strategy: ARIA (Allergic Rhinitis and its Impact on Asthma) [21, 26]
Allergic rhinitis is one of the most prevalent diseases in the world (25 % of the European Union population). Although symptoms of rhinitis appear to be 
trivial, the disease affects social activities as well as school and work performance [56]. It is often associated with or precedes asthma (including in the 
elderly) [57, 58]. Allergic rhinitis has been considered to alter AHA if not appropriately managed [7, 8]
 ARIA, a guideline for allergic rhinitis and its multimorbidity with asthma, is the first multimorbidity guideline in chronic diseases. It was developed in 
the early 2000s in collaboration with the World Health Organization using the recommended methodology for guidelines (Shekelle) [59]. It was 
updated in 2008 [60]
 It has been revised using the GRADE methodology (2010) [22, 61, 62]
 It is the most widely used guideline for rhinitis, and for rhinitis and asthma multimorbidity globally [21]
 The ARIA classification of allergic rhinitis severity has been used for the development of Health Technology Assessment guidelines, in particular in the 
US [63]
 ARIA recommendations have been adopted by government guidelines (Brazil, Portugal, Singapore)
 ARIA is implemented in 64 countries and the pocket guide of the guideline has been translated into 52 languages
 MASK‑rhinitis (MACVIA–ARIA Sentinel NetworK for allergic rhinitis) is a care pathway centred around the use of Information and Communications 
Technology (ICT) tools and a clinical decision support system (CDSS) based on ARIA [26, 34]. This tool can be used by older adults
 Over 600 scientific papers have used ARIA for the classification of allergic rhinitis in clinical practice, clinical trials, as well as epidemiologic (from pre‑
school children to the elderly [58]), basic and translational research [21]
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Classification of good practices for replication
Feasibility has been reviewed for the Finnish Asthma 
Plan (Table 6). It is expected that AIRWAYS ICPs follow-
ing the expertise raised in ARIA and GARD will have a 
similar feasibility.
Facilitating partnership for scaling up
Collaborator’s role
The ARIA programme includes over 300 members 
and AIRWAYS ICPs includes 445 members. The paper 
describing the AIRWAYS ICPs proposal is co-authored 
by 250 members (all stakeholders: health care profession-
als, social carers, patients, government officers, method-
ologists, etc.) [3]. All of the members are very committed 
to the implementation of AIRWAYS ICPs. National and 
regional groups have been initiated in all but 2 Euro-
pean Union countries. In countries where health care is 
regionalised [59], many regional groups are in place.
Role of scientific societies
AIRWAYS ICPs is in line with the mission and vision of 
scientific societies which aim to (1) promote research, 
(2) collect, assess and diffuse scientific information, (3) 
represent a scientific reference body for other scien-
tific, health and political organisations and an advocate 
towards political organisation and the general public, (4) 
encourage and provide training, continuous education 
and professional development and (5) collaborate with 
patients and lay organisations in the area of their field in 
order to lead the way towards better understanding, pre-
vention, management and eventual cure of diseases. The 
European Academy of Allergy and Clinical Immunology 
(EAACI), the European Respiratory Society (ERS), the 
European Rhinology Society (ERS), the European Union 
Geriatric Medicine Society (EUGMS), the International 
Academy of Pediatrics and the International Primary 
Care Respiratory Group (IPCRG) are the major societies 
in Europe of their respective field and are all members of 
AIRWAYS ICPs. A recent meeting on precision medicine 
in airways and allergic diseases was held at the European 
Union Parliament with these societies [77, 78]. The activ-
ities of IPCRG are summarized in Additional file 1.
Role of patient’s organisations
The goal and rationale of patient involvement in medical 
decisions is patient empowerment. Empowered patients 
know their disease. Patient empowerment commences 
with the initial consultations at the primary care level 
encompassing discussions about the patient’s ideas, con-
cerns and expectations coupled with patient education 
about the specific disease process, what can be done to 
ameliorate the disease and ultimately self-management. 
Patients have the skills and motivation to take good care 
in their everyday life, to adjust their treatment, and are 
prepared for new or potentially exacerbating situations. 
They are able to detect side-effects, contact healthcare 
professionals when necessary and they adhere to the 
treatment regime. Many tools support empowerment, 
shared decision making models and patient education. 
Patient empowerment should be included in the health 
care professional’s curriculum. For an optimal dissemina-
tion of good practices, there is a need for patient involve-
ment and empowerment.
There are recommendations to secure patient organi-
zation/patient involvement at national (e.g. The Neth-
erlands ZonMW) and also at European Union level [79, 
80].
EFA (European Federation of Allergy and airways dis-
eases patient’s association), the major patient’s organisa-
tion for respiratory and allergic diseases in Europe, has 
been very active for AIRWAYS ICPs [77, 78].
Diffusion of good practices
All European Union countries should be included.
The European Geriatric Medicine, the official organ 
of the European Union Geriatric Medicine Society 
(EUGMS), has initiated a column of the EIP on AHA to 
publish important activities of the EIP on AHA in order 
to inform the medical community [2]. Several papers 
have already been published [2, 29, 44, 81–85].
  • Reference Site Network: The Reference Site Network 
is already committed to AIRWAYS-ICPs (decision 
taken during the Montpellier meeting).
  • Action Groups: Area 5 of Action Group B3 is leading 
AIRWAYS ICPs.
  • Event and dedicated scaling up/twinning sessions: 
Several events have already taken place (Table 7).
  • Network of excellence centres in respiratory and aller-
gic diseases: It includes the Commitments for Action 
(EIP on AHA action Plan B3), Reference Sites of the 
EIP AHA, the Global Allergy and Asthma European 
Network (GA2LEN) and members of AIRWAYS 
ICPs. GA2LEN, a Sixth European Union Framework 
Programme for Research and Technological Devel-
opment (FP6) Network of Excellence, was created 
in 2005 as a vehicle to ensure excellence in research 
bringing together research and clinical institutions 
to combat fragmentation in the European research 
area and to tackle allergy in its globality [89]. The 
GA2LEN network has benefited greatly from the vol-
untary efforts of researchers who are strongly com-
mitted to this model of pan-European collaboration. 
The network was organized in order to increase net-
working for scientific and clinical projects in allergy 
and asthma around Europe.
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Implementation, key success factors and lessons learnt
Planning and initiating the service
  • Needs for AIRWAYS ICPs, in particular in elderly 
adults and co-morbid diseases, are clear. AIRWAYS 
ICPs was developed following the research priorities 
set by the World Health Organization on chronic res-
piratory diseases [90].
  • The strategy, the road map and the first implementa-
tion results have been published [4].
  • ICPs for asthma have been shown to be highly cost-
effective in different settings [15, 35]. Studies in devel-
oped and developing countries have shown a cost-
effective reduction of hospitalisations and mortality.
Setting up a system for change
  • Good understanding: The members of ARIA, 
GARD and AIRWAYS ICPs have perceived the 
need for innovation, and consider it beneficial and 
congruent with central ideas and concepts. Deploy-
ment has been made to all stakeholders including 
patients and citizens. The results of the ARIA and 
GARD initiatives are clear [13, 46, 91–98]. Since 
the same methodology is used for AIRWAYS ICPs 
enhanced by the EIP on AHA scaling up strategy, 
there is no reason for a lack of understanding. The 
present paper is co-authored by over 450 authors 
from 72 countries in order to enhance understand-
ing for different cultures, settings, health systems 
and languages.
  • Implementation of emerging technologies for predic-
tive and personalised medicine. Systems medicine is 
an emerging discipline [18, 77, 78, 99]. It combines 
high-throughput analyses of all human genes and 
their products with computational, functional and 
clinical studies. The aim is to gain detailed under-
standing of disease mechanisms, and how they vary 
between different patient groups. This understand-
ing can be exploited for predictive and personal-
ised medicine, according to guidelines proposed 
by the European Commission (https://www.casym.
eu). The first implementations may reach the clinic 
within the next five years for serious diseases that 
require costly treatments [100].
  • Political endorsement: Several meetings have been 
organised by the European Union. In particular, the 
Polish Priority of the Council [7, 8] which “WEL-
COMES existing networks and alliances, such as 
the Global Allergy and Asthma European Network 
(GA2LEN) and Global Alliance against Respiratory 
Diseases (GARD)”. There are recommendation: (i) to 
give appropriate consideration to prevention, early 
diagnosis and treatment, (ii) to strengthen coop-
eration with relevant stakeholders, (iii)to exchange 
best practices, (iv) to support national centres and 
existing international research networks (v) to find 
cost-effective procedures by using health technol-
ogy assessment, (vi) to improve health care system 
standards relating to chronic respiratory diseases, 
Table 7 AIRWAYS ICPs 2014 events
Date Location Event and goals
27‑02 Newcastle (UK) Launch of AIRWAYS ICPs by Dr. M Bewick, Deputy National Medical Director of NHS England, [12]
12‑05 Athens (Greece) AIRWAYS ICPs was presented to the EIP on AHA
09‑06 Copenhagen (Denmark) European Academy of Allergy and Clinical Immunology (EAACI). A symposium was organized (1000 participants) and 
a working meeting held immediately after: AIRWAYS ICPs and MACVIA–ARIA [26]
17‑08 Bahia (Brazil) WHO GARD annual meeting. Presentation of AIRWAYS ICPs and MACVIA–ARIA to the GARD members and WHO. 
Acceptance of AIRWAYS ICPs to strengthen the 2013–2020 Noncommunicable Diseases WHO Action Plan [86, 87]
16‑09 Rotterdam (NL) Annual meeting of the European Union Geriatric Medicine Society (EUGMS): Presidential lecture on AIRWAYS (T 
Strandberg, President of the Society)
09‑10 Dubrovnik (Croatia) Annual meeting of the Croatian Respiratory Society. AIRWAYS ICPs and MACVIA–ARIA were presented (M Niculinic, 
President of the Society)
16‑10 Rome (Italy) The Italian Presidency of the European Union Council has made chronic respiratory diseases one of the priorities. A 
GARD Italy meeting was held at the Ministry of Health. AIRWAYS ICPs was presented among other projects to be 
included in the Priority
20‑10 Montpellier (France) The Region Languedoc Roussillon (in collaboration with the region North England and the EIP on AHA Reference Site 
Collaborative Network) invited one member from each Reference Site to scale up AIRWAYS ICPs. The Collaborative 
Network decided to include AIRWAYS ICPs in its priorities for scaling up and implementation (M Bewick, R Pengelly, 
Secretary of State of Northern Ireland) [28, 29]
05‑11 Salzburg (Austria) Annual meeting of the Austrian Allergy Society
07‑11 Guangzhou (China) Annual meeting: Discussion for the deployment of AIRWAYS ICPs and MACVIA–ARIA in China (NS Zhong, former 
President of the Chinese Medical Association) [88]
20‑11 Oslo (Norway) Commitments for Action Oslo, Helsinki and Montpellier (K Lodrup Carlsen, T Haahtela, JB). The agreement for the 
deployment of the Finnish Allergy Programme in Norway was discussed at the Ministry of Health [43]
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(vii) to consider the use of e-Health tools and inno-
vative technologies for prevention, early diagnosis 
and treatment of chronic respiratory diseases, and 
finally (viii) to support Member States by the “Com-
mission developing and implementing effective 
policies, improving networking among institutions 
responsible for the implementation of programmes.”
A meeting at the European Union Parliament under 
the leadership of the Cyprus Presidency of the European 
Union Council [10] and a GARD meeting at the Italian 
Ministry of Health during the Presidency of the Council 
both reinforced the importance of chronic respiratory 
diseases for their early detection and management to 
improve AHA. The present document was presented at 
a meeting in Lisbon, Portugal (July 1–2, 2015) organised 
by the Reference Site Network of the EIP on AHA in col-
laboration with European Union regions and the Directo-
rate General of Health.
MACVIA-LR is supported by a strong politi-
cal endorsement at the regional level. ARIA has been 
adopted by several governmental policies. AIRWAYS 
ICPs has been launched in collaboration with NHS Eng-
land, Scotland, Northern Ireland, the Ministry of Health 
of Portugal, Poland and Lithuania and several govern-
ments of regions (e.g. Emilia Romagna, Basque Country).
  • Engagement of relevant stakeholders: In ARIA, GARD 
and AIRWAYS ICPs, all relevant stakeholders have 
been included and are highly motivated: health care 
professionals (physicians, pharmacists, nurses, physi-
otherapists and others), social workers, policy makers. 
A special effort has been made for patient empow-
erment. A European Union Parliament session led 
by EFA, the largest European patients’ organisation 
in asthma and airway diseases, has been organised 
in collaboration with MeDALL (Mechanisms of the 
Development of Allergy, FP7 project) [36, 37], in May 
2015. Professional societies and groups should be 
enlisted as active collaborators in order to enhance 
and even drive uptake at the country level.
  • Financial viability and business model: It has been 
shown that the implementation of the Finnish 
national plans, ARIA and GARD does not require 
large resources. However, AIRWAYS ICPs will 
require arrangements for the reimbursement of the 
services.
Organisational process and design choices
  • Investing in human capital: Training and reskilling 
the work force is an essential and fundamental com-
ponent of AIRWAYS ICPs. This may require initial 
and continuing investment to ensure that the work-
force possesses the appropriate knowledge, skills and 
equipment to fulfil its roles, as show by some very 
successful ARIA and GARD initiatives. AIRWAYS 
ICPs should shall go a step further, however, and be 
fully implemented countrywide. The EIP on AHA 
Reference Site Network has offered its help. The pre-
sent paper has been co-authored by many profes-
sional leaders from over 70 countries to build a global 
momentum.
  • Integrating ICT solutions: Telemedicine represents 
a possible specific advanced  tool of  ICT in chronic 
respiratory disease management and secondary pre-
vention. ICT solutions are integrated to support 
AIRWAYS ICPs implementation and the MACVIA–
ARIA Sentinel NetworK has been launched in 
Copenhagen (June 9, 2014). A clinical decision sup-
port system (CDSS) is being built and should be avail-
able at the end of the year. This system may form the 
prototype for a more complex one for asthma, COPD, 
other chronic respiratory diseases and co-morbidities.
  • Organisational changes: Currently under discussion 
but will require flexibility in order to adapt to the 
needs of different areas.
Monitoring, evaluation and dissemination
These activities have been initiated by ARIA and GARD 
at the international level, but they are also part of the 
national and regional plans for chronic respiratory dis-
eases. The Area 5 programme on chronic respiratory dis-
eases will benefit from previous expertise, successes and 
failures to propose refined and updated activities.
  • Assessment indicators: In asthma and COPD, hos-
pitalisation rates and mortality are two indica-
tors of interest and are responsive to change within 
2–3  years. In rhinitis, these indicators cannot be 
used. Control is applicable to asthma, COPD and/
or rhinitis and quality of life is applicable to all 3 dis-
eases. An economic evaluation was found to be effec-
tive in asthma in many countries [40, 74].
  • Mutual learning: Learning Networks for learning and 
sharing best practices are in place for chronic respira-
tory diseases. Scientific societies and patient’s organi-
sations are of importance in the process.
  • Dissemination activities: One of the strengths of 
ARIA and GARD, and also already AIRWAYS ICPs, 
is the great ability to disseminate information and 
guidelines in countries of the European Union and 
globally.
  • Scaling up of the new good practices: Another strength 
of ARIA and GARD is the capacity to scale up good 
practices in countries of the European Union and 
elsewhere.
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Conclusions
The scaling up strategy of AIRWAYS ICPs confirms that 
the proposed strategy of the EIP on AHA is simple and 
easy to follow. It may be used as a model for the scaling 
up strategies of other projects of the EIP on AHA.
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